ArticleInternational journal of nanomedicine2021
Platelet-Tumor Cell Hybrid Membrane-Camouflaged Nanoparticles for Enhancing Therapy Efficacy in Glioma.
Article in International journal of nanomedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 58 citations in OpenAlex.
- Protein-Based Nanomaterials for Cancer Therapy: A Comparative and Translational Perspective.Pharmaceutics · 2026Review
- Guided immunotherapy for residual solid tumor: integrating platelets and CAR T cells to reduce post-surgical recurrence.Biomarker research · 2026Review
- Platelet membrane-coated nanoparticles: Bioengineering principles, quality control, and translational opportunities.APL bioengineering · 2026Review
- Smart Cells Against Cancer: Advances in Cell-Based Drug Delivery and Diagnostics.Pharmaceutics · 2025Review
- Lipid nanoparticles: a promising tool for nucleic acid delivery in cancer immunotherapy.Medical oncology (Northwood, London, England) · 2025Review
- Research progress on mRNA drug delivery strategies in the nervous system.Nanomedicine (London, England) · 2025Review
- Recent advances in cell membrane-based biomimetic delivery systems for Parkinson's disease: Perspectives and challenges.Asian journal of pharmaceutical sciences · 2025Review
- Recent advances of engineering cell membranes for nanomedicine delivery across the blood-brain barrier.Journal of nanobiotechnology · 2025Review
- Article
- Immune response recalibration using immune therapy and biomimetic nano-therapy against high-grade gliomas and brain metastases.Asian journal of pharmaceutical sciences · 2025Review
- Research progress on platelets in glioma.Chinese medical journal · 2025Review
- Nanotherapeutics for Meningitis: Enhancing Drug Delivery Across the Blood-Brain Barrier.Biomimetics (Basel, Switzerland) · 2025Review
- Nanoplatelets modified with RVG for targeted delivery of miR-375 and temozolomide to enhance gliomas therapy.Journal of nanobiotechnology · 2024Article
- Advancements in precision nanomedicine design targeting the anoikis-platelet interface of circulating tumor cells.Acta pharmaceutica Sinica. B · 2024Review
- An Overview on the Physiopathology of the Blood-Brain Barrier and the Lipid-Based Nanocarriers for Central Nervous System Delivery.Pharmaceutics · 2024Review
- Hybrid Membrane-Coated Nanoparticles for Precise Targeting and Synergistic Therapy in Alzheimer's Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Inhibition of growth of hepatocellular carcinoma by co-delivery of anti-PD-1 antibody and sorafenib using biomimetic nano-platelets.BMC cancer · 2024Article
- Biomimetic Nano-Drug Delivery System: An Emerging Platform for Promoting Tumor Treatment.International journal of nanomedicine · 2024Review
- The role of platelets in the regulation of tumor growth and metastasis: the mechanisms and targeted therapy.MedComm · 2023Review
- Cell membrane-coated nanomaterials for cancer therapy.Materials today. Bio · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCell membrane-camouflaged nanoparticles (NPs) are drawing increasing attention because their surfaces acquire some characteristics of the cell membranes, making them a unique class of biomimetic materials for diverse applications. Modification of cell membrane or combination of different types of membranes can enhance their functionality.
methodsWe prepared platelet and tumor cell membrane camouflaged β-mangostin-loaded NPs, which were synthesized with platelet-C6 hybrid biomimetic coating, poly(lactic-co-glycolic acid), and β-mangostin (β-PCNPs). Then, we evaluated their targeting ability and anticancer activity against glioma in vitro and in vivo.
resultsBiomimetic coating enhanced active drug targeting and immune escape properties of nanocarrier in C6 and THP-1 cells, respectively, which improved their cytotoxicity. β-PCNPs were characterized to study the inherent properties of both source cells. Compared with bare β-NPs, β-PCNPs exhibited high tumor-targeting capability and induced apoptosis of C6 cells in vitro. Similarly, intravenous administration of drug through β-PCNPs resulted in enhanced tumor-targeting and exhibited excellent rate of inhibition of glioma tumor growth in mice. Moreover, the blood circulation time of drug in mice in the β-PCNP group was markedly prolonged and these mice exhibited better outcome than those in the β-NP group.
conclusionThese results provide a new strategy of utilizing PCNPs as carriers for drug delivery, which improves the targeting efficiency and therapeutic efficacy of chemotherapeutic agents for glioma therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.